http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고양이의 신장에서 Ethacrynic Acid가 PAH 분비에 미치는 영향
김용근,정진섭,김주헌,서덕준,이상호,Kim, Y.K.,Jung, J.S.,Kim, J.H.,Suh, D.J.,Lee, S.H. 대한생리학회 1982 대한생리학회지 Vol.16 No.2
The effect of ethacrynic acid (EA) on the renal secretion of PAH was examined in cat kidney. $C_{PAH}$ and $T_{PAH}$ were measured before and after infusion of EA $(0.5{\sim}50mg/kg)$ through the femoral vein. The following results were obtained: 1) In the dosage range of 0.5 to 25 mg/kg, EA increased the urine flow, and sodium and potassium excretion in dose-dependent manner, but the glomelular filtration rate was decreased as the dosage of EA was increased. 2) $C_{PAH}$ and $T_{PAH}$ were decreased by EA in the dosage range of 3 to 25 mg/kg and 1 to 50 mg/kg, respectively, in dose·dependent manner with the dosage to cause 50% inhibition of about 5 mg/kg. 3) With dosage of 0.5mg/kg, EA appeared to exert a great effect on diuretic response without the influence on $T_{PAH}$. At 10min after infusion of EA, a potent diuretic effect appeared, while $T_{PAH}$ did not show a significant change. These results suggest that the action mechanism of EA on tubular secretion of PAH may be different from that on natriuresis. 4) With dosage of 5 mg/kg, EA did not inhibit the Na-K-ATPase activity in microsomal fractions from both cortex and medulla. 5) The double reciprocal plot ($l/T_{PAH}$ versus $l/P_{PAH}$) suggested that EA inhibited the P AH secretion by a competitive pattern. However, probenecid, a prototypic inhibitor of the organic acid pump, had no influence on both the inhibitory effect of $T_{PAH}$ and the natriuretic effect by EA. These results suggest that in vivo EA altered tubular secretion of P AH through interactions with receptors that are not identical with the Na-K-ATPase.
혈액투석 환자의 투석간 체중증가에 미치는 Angiotensin 전환효소 억제제의 효과
김미경(M . K . Kim),윤태득(T . D . Yoon),서달덕(D . D . Su),이진연(J . Y . Lee),김용근(Y . K . Kim),이형걸(H . G . Lee),김태익(T . Y . Kim),최영선(Y . S . Choi),공진민(J . M . Kong) 대한내과학회 1997 대한내과학회지 Vol.52 No.5
N/A Objective: To determine the efficacy of ACE inhibitor on reducing the interdialytic HW gain of patients on maintenance hemodialysis. Methods: A randomized, double blind, placebo controlled crossover study, consisting of one 4-week baseline period and two 4-week treatment periods, which were interposed by a 2-week washout period, was conducted on 21 non-diabetic ESI4D patients on hemodialysis. During the treatment periods, patients were given either fosinopril 10 mg/day or a placebo. Interdialytic BW gain was recorded during the study period and BUN, plasma Na, osmolarity and the agiotensin II level were measured at the end of the baseline and treatment periods. Results: Eight patients were excluded from the study due to incompliance to medication and 13 patients remained in the study. During the baseline period, no correlation was found between interdialytic weight gain and BUN, Na, osmolarity and angiotens in II. There was no difference in the interdialytic weight. increment between the fosinopril-treated (1.0±0.1kg/day, mean±SE) and placebo-treated period (1.0±0.1), The weight increment in both periods was significantly less than that in the baseline period (1.2±0.2), suggesting a psychological influence of both medications on thirst. However, in 8 patients who gained 1.0 kg/day or more during the baseline period, the interdialytic HW increment in fosinopril-treated period (1.3±0.1) was significantly less than that in the placebo period (1.4±0.1, p<0.05 by paired t test). Of these patients, 6 patients gained less and 2 patients showed no difference in the fosinopril period compared with the placebo period. Conclusion: ACE inhibitor may reduce interdialytic BW gain in hemodialysis patients with moderate to high interdialytic weight increment.